BACKGROUND: PLD is a standard treatment in patients with recurrent platinum-resistant or refractory ovarian cancer. Vandetanib is an oral once daily administered inhibitor of VEGFR-, EGFR- and RET-signaling with activity in combination with chemotherapy in some solid tumours. We aimed to establish a feasible combination therapy of PLD and vandetanib in ovarian cancer. METHODS: Eligible patients were treated with PLD 50 mg/m(2) q28 and vandetanib 100 mg/d po. It was planned to recruit at least 10 patients evaluable for toxicity over 2 treatment cycles. Primary endpoints were tolerability and safety; secondary endpoint was efficacy. RESULTS: Fourteen of 15 registered patients started treatment and were evaluable for toxicity. Three patients (21%) stopped after first cycle (PD, withdrawal of consent, nausea/vomiting). The remaining 11 patients were treated for at least 2 cycles. Dose reductions of PLD and vandetanib were indicated in 4 (29%) and 5 patients (36%), respectively. The following G3/4 toxicities occurred per patient: 2 (14%) elevated liver enzymes G3, 2 (14%) neutropenia G3/4, 5 (36%) PPE G3/4, 2 (14%) mucositis G3. Tyrosine kinase inhibitor attributed side effects like hypertension or bowel perforations were not reported. Toxicity led to cessation of treatment in 4 patients (29%). Ten patients were evaluable for response: PR 1, SD 4. The median PFS was 6.7 months and median OS was 11.1 months. CONCLUSIONS: The combination of PLD 50 mg/m(2)q28 and vandetanib 100 mg/d is feasible, but may be intolerable due to reported toxicity.
BACKGROUND: PLD is a standard treatment in patients with recurrent platinum-resistant or refractory ovarian cancer. Vandetanib is an oral once daily administered inhibitor of VEGFR-, EGFR- and RET-signaling with activity in combination with chemotherapy in some solid tumours. We aimed to establish a feasible combination therapy of PLD and vandetanib in ovarian cancer. METHODS: Eligible patients were treated with PLD 50 mg/m(2) q28 and vandetanib 100 mg/d po. It was planned to recruit at least 10 patients evaluable for toxicity over 2 treatment cycles. Primary endpoints were tolerability and safety; secondary endpoint was efficacy. RESULTS: Fourteen of 15 registered patients started treatment and were evaluable for toxicity. Three patients (21%) stopped after first cycle (PD, withdrawal of consent, nausea/vomiting). The remaining 11 patients were treated for at least 2 cycles. Dose reductions of PLD and vandetanib were indicated in 4 (29%) and 5 patients (36%), respectively. The following G3/4 toxicities occurred per patient: 2 (14%) elevated liver enzymes G3, 2 (14%) neutropenia G3/4, 5 (36%) PPE G3/4, 2 (14%) mucositis G3. Tyrosine kinase inhibitor attributed side effects like hypertension or bowel perforations were not reported. Toxicity led to cessation of treatment in 4 patients (29%). Ten patients were evaluable for response: PR 1, SD 4. The median PFS was 6.7 months and median OS was 11.1 months. CONCLUSIONS: The combination of PLD 50 mg/m(2)q28 and vandetanib 100 mg/d is feasible, but may be intolerable due to reported toxicity.
Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: D K Moscatello; M Holgado-Madruga; A K Godwin; G Ramirez; G Gunn; P W Zoltick; J A Biegel; R L Hayes; A J Wong Journal: Cancer Res Date: 1995-12-01 Impact factor: 12.701
Authors: Katherine Thornton; Geoffrey Kim; V Ellen Maher; Somesh Chattopadhyay; Shenghui Tang; Young Jin Moon; Pengfei Song; Anshu Marathe; Suchitra Balakrishnan; Hao Zhu; Christine Garnett; Qi Liu; Brian Booth; Brenda Gehrke; Robert Dorsam; Leigh Verbois; Debasis Ghosh; Wendy Wilson; John Duan; Haripada Sarker; Sarah Pope Miksinski; Lisa Skarupa; Amna Ibrahim; Robert Justice; Anthony Murgo; Richard Pazdur Journal: Clin Cancer Res Date: 2012-06-04 Impact factor: 12.531
Authors: Richard H de Boer; Óscar Arrieta; Chih-Hsin Yang; Maya Gottfried; Valorie Chan; Johann Raats; Filippo de Marinis; Raymond P Abratt; Jürgen Wolf; Fiona H Blackhall; Peter Langmuir; Tsveta Milenkova; Jessica Read; Johan F Vansteenkiste Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: S N Holden; S G Eckhardt; R Basser; R de Boer; D Rischin; M Green; M A Rosenthal; C Wheeler; A Barge; H I Hurwitz Journal: Ann Oncol Date: 2005-05-19 Impact factor: 32.976
Authors: Christina M Annunziata; Amanda J Walker; Lori Minasian; Minshu Yu; Herbert Kotz; Bradford J Wood; Katherine Calvo; Peter Choyke; Daniel Kimm; Seth M Steinberg; Elise C Kohn Journal: Clin Cancer Res Date: 2010-01-12 Impact factor: 12.531
Authors: Mark P Saunders; Richard Wilson; Marc Peeters; Robert Smith; Alex Godwood; Stuart Oliver; Eric Van Cutsem Journal: Cancer Chemother Pharmacol Date: 2009-01-29 Impact factor: 3.333
Authors: Robert L Coleman; James Moon; Anil K Sood; Wei Hu; James E Delmore; Albert J Bonebrake; Garnet L Anderson; Setsuko K Chambers; Maurie Markman Journal: Eur J Cancer Date: 2014-04-04 Impact factor: 9.162
Authors: Jo Morrison; Clemens Thoma; Richard J Goodall; Thomas J Lyons; Kezia Gaitskell; Alison J Wiggans; Andrew Bryant Journal: Cochrane Database Syst Rev Date: 2018-10-16
Authors: Robert L Coleman; James Moon; Anil K Sood; Wei Hu; James E Delmore; Albert J Bonebrake; Garnet L Anderson; Setsuko K Chambers; Maurie Markman Journal: Eur J Cancer Date: 2014-04-04 Impact factor: 9.162